C4 Therapeutics, Inc.
C4 Therapeutics, Inc. (CCCC) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CCCC · as of Jun 8, 2026
Key Statistics
Explore C4 Therapeutics, Inc. Data
cccc stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 14 · Buy rate: 71.4%
The CCCC analyst consensus is Buy, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month price target is $7.00, representing +94.71% upside from the current price of $3.60.
Competitors & Peers
cccc competitorsCCCC
ARMP
CDXS
CYBN
IMDX
MISTStock Performance
Full HistoryAbout C4 Therapeutics, Inc.
C4 Therapeutics, Inc. a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, …
what is c4 therapeutics, inc. · cccc stock overview · c4 therapeutics, inc. company profile · who is c4 therapeutics, inc. ceo · cccc NASDAQ · c4 therapeutics, inc. headquarters · c4 therapeutics, inc. business segments
About Stock Overview & Key Data
C4 Therapeutics, Inc. (CCCC) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 2, 2020. As of the latest trading session, CCCC stock price is $3.60, with a market capitalization of $297.8M. The stock has returned +113.99% over the past 12 months and +88.22% year-to-date.
According to 14 Wall Street analysts, the consensus rating for C4 Therapeutics, Inc. stock is Buy, with an average 12-month price target of $7.00. In fiscal year 2025, C4 Therapeutics, Inc. reported revenue of $35.9M and net income of -$105.0M. For detailed data — including C4 Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, C4 Therapeutics, Inc. (CCCC) stock price is $3.60. The stock is traded on NASDAQ under the ticker symbol CCCC. The 52-week range is $1.36 – $4.60.